STUDY OF APOLIPOPROTEIN B MRNA EDITING CATALYTIC POLYPEPTIDE-LIKE 3B EXPRESSION IN PLASMA CELL MYELOMA

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria.

2 Department of Internal Hematology,* Faculty of Medicine, Alexandria University, Alexandria.

3 Department of Clinical and chemical Pathology , Faculty of Medicine, Alexandria University

Abstract

Multiple Myeloma (MM) is a genetically and clinically heterogeneous malignancy of plasma cells that progresses through distinct stages from MGUS to advanced disease. Its pathogenesis involves complex interactions between genetic mutations, the bone marrow microenvironment, and immune dysregulation. Among the key molecular drivers, APOBEC3B has emerged as a significant contributor to MM development and progression. This cytidine deaminase enzyme promotes genomic instability through C-to-U deamination in single-stranded DNA, leading to a mutational signature frequently observed in MM. Elevated APOBEC3B expression is associated with poor prognosis, increased tumor heterogeneity, and potential resistance to therapy. Understanding the role of APOBEC3B in MM not only enhances insights into disease biology but also opens new avenues for biomarker development and targeted therapeutic strategies.
AIM:
The aim of this study was to study expression of APOBEC3B in Plasma cell myeloma and correlate it with disease characteristics.
PATIENT AND METHODS:
Subjects: This study was conducted on 50 newly diagnosed plasma cell myeloma patients of both sexes, diagnosed according to the International Myeloma Working Group (IMWG) criteria. admitted to Alexandria Main University Hospital and 30 healthy individuals of matching age and sex as a control group.

Keywords

Files

Share

How to cite

Statistics